ÂÜÀòÂÒÂ×

Tamara A. Seymour was appointed to our Board of Directors in March 2021. Ms. Seymour has more than 30 years of life sciences industry experience including 20 years as Chief Financial Officer. She currently serves as a board member and audit committee chair of Kintara Therapeutics, Inc. and KemPharm, Inc., both publicly-traded clinical-stage drug development companies. Ms. Seymour served as Interim CFO of Immunic, Inc., a publicly-traded clinical-stage drug development company in 2019. She served as CFO of several companies including Signal Genetics, Inc., a publicly-traded molecular diagnostics company, from 2014 to 2017, HemaQuest Pharmaceuticals, Inc., a venture-backed clinical-stage drug development company, from 2010 to 2014 and Favrille, Inc., a publicly-traded clinical-stage drug development company, from 2001 to 2009. While at these companies, she led multiple private and public financings, including Favrille’s IPO. In addition, she was instrumental in M&A transactions and led the finance, investor relations, human resources, administration and managed care and payor reimbursement functions. Earlier in her career, she spent eight years in public accounting with Deloitte & Touche LLP and PricewaterhouseCoopers LLP, including three years as audit manager. Ms. Seymour is a Certified Public Accountant (inactive). She received an MBA, emphasis in Finance, from Georgia State University, and a BBA, emphasis in Accounting, from Valdosta State University. Ms. Seymour served on the Board of Directors of Beacon Discovery, Inc. from 2018 until their acquisition in 2021.